1223 completed. 1223 Phase 2, 122 Phase 1, 85 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1223 | Completed 1223 |
| Phase 1 | 122 | Completed 122 |
| Phase 3 | 85 | Completed 85 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic Rhinitis INI-2004, Placebo - Allergic Rhinitis Due to Allergens, Rhinitis Allergic | Phase 2 | Completed | Inimmune Corporation | 78 | 2026-01-19 | 2026-04-29 |
| Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma Budesonide, Formoterol Fumarate, and Umeclidinium Bromide, Budesonide and Formoterol Fumarate, Placebo for CP006 Inhalation Powder - Asthma | Phase 2 | Completed | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | 150 | 2025-11-21 | 2026-09-08 |
| Phase 2b Study of EVO756 in Adults With Atopic Dermatitis EVO756, Placebo control - Atopic Dermatitis | Phase 2 | Completed | Evommune, Inc. | 121 | 2025-08-26 | 2026-10-05 |
| Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) Rademikibart in prefilled syringe, Matching placebo in prefilled syringe - Asthma Acute | Phase 2 | Completed | Connect Biopharm LLC | 160 | 2025-08-08 | 2026-09-16 |
| A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis SHR-1819 Injection, SHR-1819 Injection Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 108 | 2025-08-06 | 2026-08-27 |
| Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis TQC2938 injection, TQC2938 Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 136 | 2025-07-31 | 2026-02-10 |
| A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis MG-K10/Placebo - Atopic Dermatitis (AD) | Phase 2 | Completed | Shanghai Mabgeek Biotech.Co.Ltd | 60 | 2025-06-30 | 2026-08-03 |
| M-Gard Particulate EW Efficacy Study on Seasonal Allergic Rhinitis M-Gard, Placebo - Allergic Rhinitis Due to Grass Pollens | Phase 2 | Completed | RDC Clinical Pty Ltd | 20 | 2025-06-27 | 2026-03-06 |
| Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge ETH47, Placebo - Asthma (Diagnosis) | Phase 2 | Completed | Ethris GmbH | 50 | 2025-06-24 | 2026-11-03 |
| Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis ARQ-151 cream 0.05% - Atopic Dermatitis (Eczema) | Phase 2 | Completed | Arcutis Biotherapeutics, Inc. | 101 | 2025-06-09 | 2025-12-10 |
| iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B) - Pulmonary Aspergillosis, Chronic Pulmonary Aspergillosis | Phase 2 | Completed | Radboud University Medical Center | 10 | 2025-05-01 | 2026-08-18 |
| Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis VC005 Placebo group, VC005 groups - Atopic Dermatitis | Phase 2 | Completed | Jiangsu vcare pharmaceutical technology co., LTD | 118 | 2025-04-28 | 2026-04-13 |
| A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis CGB-500 Ointment with 1% tofacitinib, Ruxolitinib 1.5% Cream QD - Atopic Dermatitis (AD) | Phase 2 | Completed | CAGE Bio Inc. | 3 | 2025-04-21 | 2026-04-01 |
| A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001 CHF 6001 - Asthma | Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 50 | 2025-03-28 | 2025-11-26 |
| Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) EVO756, Placebo control - Chronic Spontaneous Urticaria | Phase 2 | Completed | Evommune, Inc. | 182 | 2025-03-20 | 2026-07-01 |
| A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis LNK01004 ointment 0.3%, LNK01004 ointment 1.0%, Vehicle - Atopic Dermatitis | Phase 2 | Completed | Lynk Pharmaceuticals Co., Ltd | 75 | 2025-03-18 | 2026-01-14 |
| A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis Pumecitinib Nasal Spray 0.3%, Pumecitinib Nasal Spray 0.6%, Placebo (twice daily) - Seasonal Allergic Rhinitis | Phase 2 | Completed | Prime Gene Therapeutics Co., Ltd. | 179 | 2025-03-12 | 2026-09-09 |
| Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis TQH2722 injection, TQH2722 Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 169 | 2025-03-10 | 2025-08-12 |
| Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults JT002 Nasal spray, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Shanghai JunTop Biosciences Co., LTD | 370 | 2025-02-24 | 2025-06-11 |
| Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis EVO301, Placebo - Atopic Dermatitis (AD), Eczema | Phase 2 | Completed | Evommune, Inc. | 71 | 2025-02-13 | 2025-12-04 |
Showing 20 of 1223. Sign in to see all of them.
Asthma (481) · Dermatitis, Atopic (267) · Rhinitis, Allergic (95) · Rhinitis, Allergic, Seasonal (91) · Eczema (68) · Food Hypersensitivity (41) · Peanut Hypersensitivity (38) · Conjunctivitis, Allergic (36) · Eosinophilic Esophagitis (34) · Pruritus (26) · Chronic Urticaria (25) · Rhinitis (24) · Sarcoidosis (23) · Pulmonary Disease, Chronic Obstructive (22)
Immune System Diseases (1214) · Hypersensitivity, Immediate (1118) · Respiratory Tract Diseases (687) · Respiratory Hypersensitivity (660) · Lung Diseases (501) · Bronchial Diseases (489) · Lung Diseases, Obstructive (481) · Skin and Connective Tissue Diseases (359) · Skin Diseases (340) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (301) · Genetic Diseases, Inborn (297) · Skin Diseases, Eczematous (273) · Skin Diseases, Genetic (272) · Dermatitis (267)
Omalizumab (36) · Fluticasone (34) · Formoterol Fumarate (26) · Albuterol (25) · Budesonide (23) · montelukast (23) · dupilumab (20) · Mometasone Furoate (18) · Beclomethasone (14) · Sodium Chloride (12) · Salmeterol Xinafoate (10) · fluticasone furoate (10) · lebrikizumab (10) · Cholecalciferol (9) · Tiotropium Bromide (9)
GlaxoSmithKline (67) · Novartis Pharmaceuticals (47) · AstraZeneca (35) · National Institute of Allergy and Infectious Diseases (NIAID) (25) · Chiesi Farmaceutici S.p.A. (22) · Boehringer Ingelheim (21) · Pfizer (20) · Genentech, Inc. (16) · Sanofi (15) · Johns Hopkins University (14) · Novartis (13) · Regeneron Pharmaceuticals (13) · Organon and Co (12) · University of North Carolina, Chapel Hill (12) · ALK-Abelló A/S (11)
United States (592) · Germany (239) · Canada (208) · United Kingdom (159) · Poland (128) · Spain (69) · Hungary (67) · France (66) · Australia (62) · Japan (57) · Netherlands (57) · Bulgaria (56) · Czechia (52) · Russia (51) · China (46)
Wesley Burks, MD (9) · Dave Singh, MD (8) · Robert Wood, MD (8)
PMID 27881132, PMID 36326435, PMID 36408587, PMID 36472162, PMID 38814736, PMID 39393433, PMID 19001265, PMID 19748656, PMID 24010736, PMID 24184147, PMID 24836393, PMID 25006719, PMID 26001563, PMID 26283085, PMID 26704701, PMID 28758192, PMID 29656145, PMID 30978404, PMID 33217063, PMID 33305842, PMID 34089147, PMID 34379802, PMID 34389504, PMID 34773261, PMID 35636689, PMID 36253275, PMID 36440464, PMID 36718018, PMID 39035788, PMID 39575597, PMID 41615410, PMID 11398072, PMID 14619332, PMID 16387596, PMID 16895558, PMID 17021320, PMID 17346444, PMID 17631952, PMID 17935764, PMID 17950857, PMID 18244953, PMID 18403223, PMID 18566548, PMID 18668591, PMID 18699936, PMID 18787222, PMID 18946234, PMID 18951617, PMID 19136369, PMID 19196814
2009 (17), 2014 (12), 2016 (12), 2015 (11), 2018 (10), 2019 (8), 2008 (7), 2017 (6), 2023 (5), R01AT004435 (3), U19AI066738 (3), 2004 (2), P01HL158507 (2), U19AI104209 (2), U54AI117804 (2)